Clinical Trial Update: A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating olinciguat (IW-1701), a soluble guanylate cyclase stimulator, in sickle cell disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• olinciguat (IW-1701)

Snippet

Sponsor: Cyclerion Therapeutics | Conditions: Sickle Cell Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-07-21